CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 12 enrolled
Drug / intervention
Cologuard +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06173375
NCT06173375N/ACompleted
CompareCT.gov

Comparative Effectiveness Pilot Trial of Mailed Cologuard Outreach to Mailed FIT Outreach

University of California, San Diego·interventional·Posted Dec 15, 2023·Updated May 12, 2026

In Brief

A clinical study evaluating Cologuard and Fecal Immunochemical Test for Colorectal Cancer. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The objective of this pilot study is to compare the effectiveness of mailed outreach of two stool based tests, Cologuard and the fecal immunochemical test (FIT) in screening eligible adults ages 45-49 receiving care at the University of California San Diego Health system.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedDec 15, 2023
Enrollment StartMay 15, 2024
Primary CompletionDec 31, 2024
Study CompletionDec 31, 2025
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 2.5 years ago

Interventions

Cologuardother

Multi-target stool DNA test for colorectal cancer screening implemented by Exact Sciences. Cologuard has 94% sensitivity and 87% specificity to detect colorectal cancer.

Fecal Immunochemical Testother

Stool blood test for colorectal cancer screening. FIT has 75% sensitivity and 90% specificity to detect colorectal cancer.